Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer

Stopped study was on hold for protocol redesign; decided to not move forward with study.

Conditions

• Metastatic Anaplastic Thyroid Cancer
• Locally Advanced Anaplastic, Undifferentiated Thyroid Cancer

Interventions

• DRUG: Ceritinib

Sponsor

University of Texas Southwestern Medical Center

Collaborators

• [object Object]